Annual report pursuant to Section 13 and 15(d)

Accounting Policies - Additional Information (Detail)

v3.3.1.900
Accounting Policies - Additional Information (Detail)
$ in Thousands
3 Months Ended 4 Months Ended 12 Months Ended
Dec. 31, 2015
USD ($)
Sep. 30, 2015
USD ($)
Jun. 30, 2015
USD ($)
Mar. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Sep. 30, 2014
USD ($)
Jun. 30, 2014
USD ($)
Mar. 31, 2014
USD ($)
Apr. 24, 2015
USD ($)
Dec. 31, 2015
USD ($)
segment
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Dec. 31, 2009
USD ($)
Accounting Policies [Line Items]                            
Maturity period of liquid investments                   3 months        
Maturity period of financial instruments                   Greater than three months and less than one year        
Collaboration revenue $ 6,024 $ 6,737 $ 4,025 $ 1,374 $ 5,653 $ 4,803 $ 4,929 $ 11,731   $ 18,160 $ 27,116 $ 29,882    
Direct and indirect development costs                   $ 30,000        
Revenue recognized on a proportional performance basis under the collaboration agreement                         $ 30,000  
Revenue recognized                           $ 22,000
Number of operating segments | segment                   1        
Restricted stock unit awards [Member]                            
Accounting Policies [Line Items]                            
Award vesting period                   4 years        
Collaborative Arrangement [Member] | Teva Pharmaceutical Industries Ltd. [Member]                            
Accounting Policies [Line Items]                            
Proceeds from advance reimbursement research and development                 $ 27,000          
Hold-back amount and third-party expenses deducted from advanced reimbursement payment                 3,800          
Hold-back amount deducted from advanced reimbursement payment                 3,000          
Third-party expenses deducted from advanced reimbursement payment                 $ 800          
Collaboration revenue                   $ 18,200